厄贝沙坦联合氨氯地平治疗高血压糖尿病肾病的疗效

Curative Effect of Irbesartan and Amlodipine in Treatment of Hypertension Patients with Diabetic Nephropathy

目的对厄贝沙坦联合氨氯地平治疗高血压糖尿病肾病的疗效进行研究。方法以数字随机法将该院收治的70例高血压糖尿病肾病患者分为观察组和对照组,给予观察组厄贝沙坦联合氨氯地平治疗,给予对照组厄贝沙坦单药治疗,将两组治疗前后的血压和尿液检查相关指标变化情况。结果治疗前,两组的收缩压、舒张压和24 h尿白蛋白、24 h尿蛋白定量、尿β2-微球蛋白差异无统计学意义(P>0.05)。治疗后,观察组的收缩压、舒张压得到显著改善,且24 h尿白蛋白、24 h尿蛋白定量、尿β2-微球蛋白也得到显著降低,与对照组相比,差异有统计学意义(P<0.05)。结论厄贝沙坦联合氨氯地平在控制血压、减轻肾损伤等方面具有明显优势,值得推广。

Objective To research the curative effect of irbesartan and amlodipine in treatment of hypertension patients with diabetic nephropathy. Methods 70 cases of hypertension patients with diabetic nephropathy admitted and treated in our hospital were randomly divided into two groups, the observation group were treated with irbesartan and amlodipine, the con-trol group were treated with single irbesartan, and the changes of blood pressure and indicators in relation to urine examina-tion of the two groups before and after treatment were observed. Results Before treatment, the differences in the systolic pressure and diastolic pressure, 24h urinary albumin, 24h urine protein quantitation and urine β-microglobulin were not ob-vious（P〉0.05）, after treatment, the systolic pressure and diastolic pressure in the observation group were obviously improved, and the 24h urinary albumin, 24h urine protein quantitation and urine β-macroglobulin obviously decreased, and the dif-ferences were obvious compared with those in the control group（P〈0.05）. Conclusion Irbesartan and amlodipine has an ob-vious advantage in controlling blood pressure and reliving renal injury, which is worth promotion.